These findings demonstrate that Idelalisib targets multiple mechanisms of CLL cell survival by not only direct inhibition of the PI3K signaling pathway but also by inhibition of extrinsic activation of this pathway by microenvironmental stimuli from CD40L, BAFF, TNF-α, and fibronectin. The gene discussed is PIK3CG; the disease is B-cell chronic lymphocytic leukemia.